Related Experiment Video

Updated: Jul 7, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.5K

Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter,

Conor B Driscoll1, Jordan M Rich2, Christopher Yang3

  • 1Department of Urology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Arkes 23, Chicago, IL, 60611, USA. conor.driscoll@northwestern.edu.

World Journal of Urology
|February 26, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
InflammationProstate cancerTumor necrosis factor alpha inhibitorsUrologic cancer

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...